NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free BPTH Stock Alerts $4.86 +0.26 (+5.65%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$4.41▼$5.5050-Day Range$4.60▼$11.2052-Week Range$4.41▼$44.80Volume34,171 shsAverage Volume20,966 shsMarket Capitalization$3.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Bio-Path alerts: Email Address Bio-Path MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($20.80) to ($15.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.72 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Bio-Path. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.68% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently decreased by 14.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTH. Previous Next 3.1 News and Social Media Coverage News SentimentBio-Path has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bio-Path this week, compared to 1 article on an average week.Search Interest3 people have searched for BPTH on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($20.80) to ($15.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Path is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Path is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Bio-Path Stock (NASDAQ:BPTH)Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Read More BPTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTH Stock News HeadlinesMarch 15, 2024 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.comMarch 13, 2024 | insidermonkey.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 11, 2024 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Posts Earnings ResultsMarch 10, 2024 | seekingalpha.comBio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call TranscriptMarch 10, 2024 | finance.yahoo.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | msn.comWhy Bio-Path Holdings Shares Are Falling TodayMarch 8, 2024 | msn.comBio-Path files to sell 1.15M shares of common stock, warrantsMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 8, 2024 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Reports Full Year 2023 Financial ResultsMarch 8, 2024 | globenewswire.comBio-Path Holdings Reports Full Year 2023 Financial ResultsMarch 7, 2024 | benzinga.comBio-Path Holdings's Earnings: A PreviewMarch 1, 2024 | globenewswire.comBio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024February 24, 2024 | msn.comBio-Path Holdings (BPTH) Price Target Increased by 1900.00% to 244.80February 22, 2024 | benzinga.comBio-Path Hldgs Stock (NASDAQ:BPTH) Dividends: History, Yield and DatesFebruary 21, 2024 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Announces 1-for-20 Reverse Stock SplitFebruary 21, 2024 | finance.yahoo.comBio-Path Holdings Announces 1-for-20 Reverse Stock SplitFebruary 21, 2024 | globenewswire.comBio-Path Holdings Announces 1-for-20 Reverse Stock SplitFebruary 10, 2024 | investing.comBio Path Holdings Inc (BPTH)January 23, 2024 | wsj.comBio-Path Holdings Inc.January 17, 2024 | businesswire.comPragma Bio and DayTwo Join Forces to Illuminate the Path to IBD Disease ManagementJanuary 14, 2024 | seekingalpha.comBPTH Bio-Path Holdings, Inc.January 11, 2024 | msn.comBio-Path concludes first cohort of Phase I lymphoma trialJanuary 10, 2024 | finance.yahoo.comBio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia PatientsDecember 22, 2023 | msn.comBio-Path files to sell sharesDecember 14, 2023 | finance.yahoo.comBio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid LeukemiaNovember 20, 2023 | finance.yahoo.comBio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call TranscriptSee More Headlines Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today3/18/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Profitability EPS (Most Recent Fiscal Year)($40.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-375.74% Return on Assets-248.63% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book6.85Miscellaneous Outstanding Shares680,000Free Float658,000Market Cap$3.30 million OptionableOptionable Beta0.66 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Peter H. Nielsen MBA (Age 75)Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer Comp: $722.68kMr. Douglas P. Morris (Age 68)Co-Founder, Director of Investor Relations, Secretary & Director Comp: $110.68kMr. Michael Hickey M.B.A.VP of Clinical OperationsMr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationDr. Ana Tari Ashizawa Ph.D.MBA, Senior Vice President of Research, Development & Clinical DesignKey CompetitorsAridis PharmaceuticalsNASDAQ:ARDSFirst Wave BioPharmaNASDAQ:FWBISynaptogenixNASDAQ:SNPXNotable LabsNASDAQ:NTBLNeuBase TherapeuticsNASDAQ:NBSEView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 117,914 shares on 3/11/2024Ownership: 39.710%Vanguard Group Inc.Bought 117,914 shares on 2/15/2024Ownership: 2.186%View All Institutional Transactions BPTH Stock Analysis - Frequently Asked Questions How have BPTH shares performed in 2024? Bio-Path's stock was trading at $9.26 at the beginning of the year. Since then, BPTH stock has decreased by 47.5% and is now trading at $4.86. View the best growth stocks for 2024 here. Are investors shorting Bio-Path? Bio-Path saw a decline in short interest in the month of February. As of February 29th, there was short interest totaling 16,500 shares, a decline of 14.5% from the February 14th total of 19,300 shares. Based on an average daily trading volume, of 9,700 shares, the short-interest ratio is presently 1.7 days. Currently, 2.7% of the shares of the stock are short sold. View Bio-Path's Short Interest. When is Bio-Path's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BPTH earnings forecast. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings data on Friday, March, 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($5.40). During the same quarter in the prior year, the company earned ($10.60) earnings per share. When did Bio-Path's stock split? Shares of Bio-Path reverse split before market open on Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC). Who are Bio-Path's major shareholders? Bio-Path's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (39.71%) and Vanguard Group Inc. (2.19%). View institutional ownership trends. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BPTH) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.